Twist Bioscience Co. (NASDAQ:TWST) Director Sells $250,000.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $50.00, for a total transaction of $250,000.00. Following the sale, the director now directly owns 16,641 shares in the company, valued at $832,050. This represents a 23.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Robert Chess also recently made the following trade(s):

• On Thursday, December 5th, Robert Chess sold 3,504 shares of Twist Bioscience stock. The shares were sold at an average price of $51.85, for a total transaction of $181,682.40.
• On Monday, November 11th, Robert Chess sold 3,600 shares of Twist Bioscience stock. The stock was sold at an average price of $47.26, for a total transaction of $170,136.00.

Twist Bioscience Stock Down 3.4 %

TWST opened at $43.60 on Monday. The company has a 50 day moving average of $46.40 and a two-hundred day moving average of $46.41. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The company has a market cap of $2.59 billion, a P/E ratio of -12.11 and a beta of 1.85.

Institutional Trading of Twist Bioscience

A number of institutional investors have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB acquired a new position in shares of Twist Bioscience during the third quarter worth about $34,000. Signaturefd LLC lifted its position in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in Twist Bioscience in the 2nd quarter worth approximately $61,000. Beaird Harris Wealth Management LLC acquired a new stake in Twist Bioscience in the third quarter valued at approximately $95,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TWST. Barclays lowered their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Scotiabank lifted their price target on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a report on Tuesday, November 19th. Leerink Partners increased their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Evercore ISI raised their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Wolfe Research started coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.